Literature DB >> 24702822

Inclusion and exclusion criteria for epilepsy clinical trials-recommendations from the April 30, 2011 NINDS workshop.

Evan Fertig1, Brandy E Fureman2, Gregory K Bergey3, Mary Ann Brodie4, Dale C Hesdorffer5, Deborah Hirtz6, Eric H Kossoff7, W Curt LaFrance8, Mark Versavel9, Jacqueline French10.   

Abstract

On April 30th, 2011 the National Institute of Neurological Disorders and Stroke (NINDS) held a workshop to identify key problems in recent epilepsy clinical trials and propose approaches to address the barriers that impede development of new therapeutic options for epilepsy. Preliminary recommendations were made for selection criteria for subjects entered into epilepsy trials that maximize the scientific impact of the trial and increase the ability to recruit appropriate subjects efficiently and safely. These recommendations were further refined by the authors following the workshop, and subsequently shared with all NINDS workshop participants and with the participants of the 2011 AED XI workshop on epilepsy trials (approximately 200 participants) for further comment. The working group agreed to a final set of criteria that include updated considerations of subject age, clinical semiology, EEG and imaging results, use of prior and current therapies, co-occurring conditions, and suicidality, among others. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical trial methodology; Comorbidity; Participant selection criteria; Recruitment

Mesh:

Substances:

Year:  2014        PMID: 24702822      PMCID: PMC4028380          DOI: 10.1016/j.eplepsyres.2014.02.011

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  16 in total

1.  An eight-year perspective on the relationship between the duration of abstinence and other aspects of recovery.

Authors:  Michael L Dennis; Mark A Foss; Christy K Scott
Journal:  Eval Rev       Date:  2007-12

Review 2.  Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force.

Authors:  W Curt LaFrance; Gus A Baker; Rod Duncan; Laura H Goldstein; Markus Reuber
Journal:  Epilepsia       Date:  2013-09-20       Impact factor: 5.864

Review 3.  Felbamate: consensus of current clinical experience.

Authors:  John M Pellock; Edward Faught; Ilo E Leppik; Shlomo Shinnar; Mary L Zupanc
Journal:  Epilepsy Res       Date:  2006-08-04       Impact factor: 3.045

4.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

5.  Serum -glytamyl transpeptidase activity in liver disease.

Authors:  J B Whitfield; R E Pounder; G Neale; D W Moss
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

6.  Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  A Krumholz; S Wiebe; G Gronseth; S Shinnar; P Levisohn; T Ting; J Hopp; P Shafer; H Morris; L Seiden; G Barkley; J French
Journal:  Neurology       Date:  2007-11-20       Impact factor: 9.910

Review 7.  Psychiatric comorbidities in epilepsy.

Authors:  W Curt LaFrance; Andres M Kanner; Bruce Hermann
Journal:  Int Rev Neurobiol       Date:  2008       Impact factor: 3.230

8.  Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota.

Authors:  D C Hesdorffer; G Logroscino; G D Cascino; W A Hauser
Journal:  Neurology       Date:  2007-07-03       Impact factor: 9.910

Review 9.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

Review 10.  Pharmacokinetics in the child.

Authors:  W R Crom
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

View more
  1 in total

1.  Suspend or amend? Randomized controlled trial on neuropsychological rehabilitation for epilepsy: A COVID-19 impact.

Authors:  Shivani Sharma; Ashima Nehra; Shivam Pandey; Madhavi Tripathi; Achal Srivastava; M V Padma; Ajay Garg; R M Pandey; Sarat Chandra; Manjari Tripathi
Journal:  Epilepsy Behav Rep       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.